Epoetin alfa offers clinically significant improvements in the quality of life of anaemic cancer patients

Current Medical Research and Opinion, Supplement

Volumn 21, Issue 2, 2005, Pages

  Cella, D ^a   Zagari, M J ^a   Vandoros, C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; PLACEBO;

ANAMNESIS; ANEMIA; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FUNCTIONAL ASSESSMENT; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNET; MAJOR CLINICAL STUDY; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; CHEMICALLY INDUCED DISORDER; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOPHYSIOLOGY; QUESTIONNAIRE; STATISTICAL MODEL;

ANEMIA; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 33645961584     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/174234305X13806     Document Type: Article

References (10)

1. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripartite assessment survey. Semin Hematol. 1997;34:4-12
2. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist 2000;5:353-60
3. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol. 1998;25(suppl 7):43-6
4. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997;15:1218-34
5. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefits in chemotherapy patients treated with epoetin alfa are independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol. 1998;16:3412-25
6. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172-9
7. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34 (suppl 2):13-19
8. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms of cancer with the functional assessment of cancer therapy (FACT) measurement system. J Pain Sympt Manage. 1997;13:63-74
9. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-75
10. Kazis LE, Andersen JJ, Meenan RF. Effect sizes for interpreting changes in health studies. Med Care. 1989;27:S178-S189